Telaprevir and Ribavirin Interaction: Higher Ribavirin Levels Are Not Only Due to Renal Dysfunction during Triple Therapy

被引:3
作者
Gutierrez-Valencia, Alicia [1 ,2 ]
Ruiz-Valderas, Rosa [1 ,2 ]
Ben-Marzouk-Hidalgo, Omar J. [1 ,2 ]
Torres-Cornejo, Almudena [1 ,2 ]
Espinosa, Nuria [1 ]
Castillo-Ferrando, Juan R. [3 ]
Viciana, Pompeyo [1 ,2 ]
Lopez-Cortes, Luis F. [1 ,2 ]
机构
[1] Hosp Univ Virgen del Rocio, Enfermedades Infecciosas Microbiol & Med Prevent, Seville, Spain
[2] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBiS, Seville, Spain
[3] Hosp Univ Virgen del Rocio, Farmacol Clin, Seville, Spain
关键词
CHRONIC HEPATITIS-C; SUSTAINED VIROLOGICAL RESPONSE; PEGYLATED INTERFERON; INFECTED PATIENTS; COINFECTED PATIENTS; VIRUS-INFECTION; PEGINTERFERON-ALPHA; TUBULAR SECRETION; DRUG-INTERACTIONS; PLUS RIBAVIRIN;
D O I
10.1128/AAC.04795-14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A higher incidence of anemia has been observed during the treatment of hepatitis C virus genotype 1 (HCV-1) infection with pegylated alpha interferon (pegIFN-alpha), ribavirin, and telaprevir. We assessed the impacts that concomitant administration of telaprevir and changes in the glomerular filtration rate have on ribavirin plasma levels. The minimum concentrations of ribavirin in plasma (ribavirin C-min) determined during triple therapy including telaprevir were compared with those observed after telaprevir withdrawal and those observed in the same subjects and in a large cohort during a previous course of pegIFN-alpha plus ribavirin. Intensive pharmacokinetic sampling for ribavirin was performed at steady state during the triple-therapy phase. Ribavirin levels were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Twenty-seven HCV-1/HIV-coinfected patients were enrolled. The median ribavirin C-min for triple therapy (4.08 mu g/ml; range, 2.14 to 5.56 mu g/ml) was higher than that observed after telaprevir withdrawal (1.96 mu g/ml; range, 0.41 to 3.45 mu g/ml) (P < 0.001) and that observed for 125 HCV-1/HIV-coinfected patients treated only with pegIFN-alpha plus ribavirin (1.65 mu g/ml; range, 0.41 to 5.56 mu g/ml) (P < 0.001). The estimated glomerular filtration rate (eGFR) decreased > 20% from the baseline value in 11 of 27 patients and became normal after telaprevir removal in almost all cases. There was a negative correlation between eGFR and ribavirin clearance (r(2) = 0.257; P = 0.064) but not the ribavirin area under the concentration-time curve from 0 to 12 h (AUC(0-12)) (r(2) = 0.001; P = 0.455). Thus, there is a significant pharmacokinetic interaction between telaprevir and ribavirin that results in very high ribavirin levels, which explains the excess of toxicity observed with this drug combination. A blockade of the proximal tubular transporters might be implicated in both the increase in plasma creatinine and the high ribavirin levels.
引用
收藏
页码:3257 / 3262
页数:6
相关论文
共 38 条
[31]   Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis [J].
Recio, Eva ;
Macias, Juan ;
Rivero-Juarez, Antonio ;
Tellez, Francisco ;
Merino, Dolores ;
Jose Rios, Ma ;
Marquez, Manuel ;
Omar, Mohamed ;
Rivero, Antonio ;
Lorenzo, Sandra ;
Merchante, Nicolas ;
Pineda, Juan A. .
LIVER INTERNATIONAL, 2012, 32 (06) :1031-1032
[32]   Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials [J].
Sitole, Mugdha ;
Silva, Matthew ;
Spooner, Linda ;
Comee, Morgan K. ;
Malloy, Michael .
CLINICAL THERAPEUTICS, 2013, 35 (02) :190-197
[33]   Human organic anion transporters and human organic cation transporters mediate renal antiviral transport [J].
Takeda, M ;
Khamdang, S ;
Narikawa, S ;
Kimura, H ;
Kobayashi, Y ;
Yamamoto, T ;
Cha, SH ;
Sekine, T ;
Endou, H .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (03) :918-924
[34]   Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes [J].
Torres-Cornejo, A. ;
Ruiz-Valderas, R. ;
Jimenez-Jimenez, L. ;
Abad-Molina, C. ;
Gutierrez-Valencia, A. ;
Viciana, P. ;
Lopez-Cortes, L. F. .
JOURNAL OF VIRAL HEPATITIS, 2014, 21 (03) :178-188
[35]   Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection [J].
Tsubota, A ;
Hirose, Y ;
Izumi, N ;
Kumada, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) :360-367
[36]  
US Food and Drug Administration, 2012, TEL FULL PRESCR INF
[37]   Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients [J].
van Vlerken, L. G. ;
Huisman, E. J. ;
van Soest, H. ;
Boland, G. J. ;
Drenth, J. P. H. ;
Siersema, P. D. ;
Burger, D. M. ;
van Erpecum, K. J. .
JOURNAL OF VIRAL HEPATITIS, 2012, 19 (01) :39-46
[38]   Ribavirin Concentration Is a More Important Predictor of Sustained Viral Response Than Anemia in Hepatitis C Patients [J].
van Vlerken, Lotte G. ;
van Oijen, Martijn G. H. ;
van Erpecum, Karel J. .
GASTROENTEROLOGY, 2011, 140 (05) :1693-1694